A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY PLUS MIDOSTAURIN (PKC412) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS WITH FLT3 MUTATION NEGATIVE AML
EHA Library, Hartmut Döhner,
267763
B-SYMPTOMS, PERFORMANCE STATUS, AND RESPONSE TO FIRST THERAPY AS SURVIVAL PREDICTIVE FACTORS FOR PERIPHERAL T-CELL LYMPHOMA AT PROGRESSION/RELAPSE: A SINGLE INSTITUTE ANALYSIS
EHA Library, Yuko Shirouchi,
267785
PHARMACO-ECONOMY ANALYSIS OF THE THREATMENT WITH R-DA-EPOCH, R-CHOP, AND CHOP-LIKE REGIMENS IN HIGH-RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (UKRAINIAN MULTICENTER STUDY)
EHA Library, Kateryna Filonenko,
267804
PREBEN, PIXANTRONE, RITUXIMAB, ETOPOSIDE AND BENDAMUSTINE, IN AGGRESSIVE NON-HOGDKIN LYMPHOMA
EHA Library, Cristina barrenetxea,
267811
A PHASE 1/1B DOSE-ESCALATION TRIAL EVALUATING CPI-818, AN ORAL INTERLEUKIN-2-INDUCIBLE T-CELL KINASE INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY T-CELL LYMPHOMA
EHA Library, Mehrdad Mobasher,
267823